Skip to main content
. 2018 Feb 7;32(2):129–135. doi: 10.1007/s40259-018-0262-9

Fig. 1.

Fig. 1

Clinical development programs of European biosimilar epoetins. CIA chemotherapy-induced anemia, CKD chronic kidney disease, HD hemodialysis, IV intravenous, PD pharmacodynamic, PK pharmacokinetic, SC subcutaneous